StockData
Cosmos Health Inc. logo

Cosmos Health Inc. (COSM) stock

COSMNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30107% above fair value
$2.85+0.36 (+14.46%)

Close on Nov 17, 2026Market cap $286.81MP/E –Yield –

Cosmos Health r&d expenses

Research and development expenses are spending on new products and technology.

Cosmos Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $497.65K, down 20.2% year over year. For fiscal 2025 it was $519.36K, down 2.6% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$519.36K-2.6%
FY2024Dec 31, 2024$533.29K+223.5%
FY2023Dec 31, 2023$164.86K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$68.55K-8.2%
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$410.76K-23.0%
Q3 FY2025Sep 30, 2025$18.34K–
Q2 FY2025Jun 30, 2025$74.64K–
Q1 FY2025Mar 31, 2025$15.63K–
Q4 FY2024Dec 31, 2024$533.29K–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–

More Cosmos Health figures

See a number that looks wrong?